Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Stalkchain Analysis: FARTCOIN and VIRTUAL Receive Significant Net Inflows, POPCAT Shows Weak Inflows

Stalkchain Analysis: FARTCOIN and VIRTUAL Receive Significant Net Inflows, POPCAT Shows Weak Inflows

ChaincatcherChaincatcher2025/05/06 05:21
Show original

According to a report by Stalkchain, smart money is quietly positioning itself in multiple cryptocurrencies. AVA, FARTCOIN, and VIRTUAL are experiencing significant net capital inflows. Meanwhile, PORK and SAN, despite having relatively smaller market caps, are seeing notable capital inflows, which may indicate that institutional investors are positioning themselves early.

Additionally, HOSICO and TITCOIN are also showing strong demand. It is worth noting that the larger market cap POPCAT is experiencing weak capital inflows, which may suggest that its upward momentum is weakening.

 

 
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.